BiondVax Pharmaceuticals (BVXV) Given Daily News Sentiment Rating of 0.03

News coverage about BiondVax Pharmaceuticals (NASDAQ:BVXV) has been trending somewhat positive recently, according to Accern. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BiondVax Pharmaceuticals earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 50.3008749942632 out of 100, meaning that recent media coverage is somewhat likely to have an effect on the company’s share price in the immediate future.

BiondVax Pharmaceuticals (NASDAQ:BVXV) traded up $0.46 during midday trading on Thursday, reaching $5.98. 24,600 shares of the company traded hands, compared to its average volume of 16,500. BiondVax Pharmaceuticals has a 52-week low of $3.65 and a 52-week high of $10.75. The stock has a market capitalization of $36.07, a price-to-earnings ratio of -3.99 and a beta of 0.33.

Separately, ValuEngine lowered shares of BiondVax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st.

ILLEGAL ACTIVITY NOTICE: “BiondVax Pharmaceuticals (BVXV) Given Daily News Sentiment Rating of 0.03” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3125761/biondvax-pharmaceuticals-bvxv-given-daily-news-sentiment-rating-of-0-03.html.

About BiondVax Pharmaceuticals

BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.

Insider Buying and Selling by Quarter for BiondVax Pharmaceuticals (NASDAQ:BVXV)

Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.